Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Therapeutic Area: Head and Neck

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and a programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) inhibitor. The primary hypothesis is that lenvatinib + pembrolizumab is superior to SOC chemotherapy with respect to ORR per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review.

Therapeutic Area: Head and Neck

Lenvatinib in Combination With Pembrolizumab vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy

March 10, 2022

By clique_admin

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of

Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC

March 7, 2022

By Tyler Kalist

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA)

A Study of Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

March 7, 2022

By Support_Clique

Participants with recurrent or metastatic (R/M) squamous cell cancer of the head and neck (HNSCC) will be randomly assigned to receive pembrolizumab monotherapy [pembro mono], pembrolizumab plus chemotherapy with a platinum-based

Study of Pembrolizumab or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

March 7, 2022

By clique_admin

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally

A Study of Pembrolizumab Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

March 7, 2022

By clique_admin

The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first line treatment in participants with recurrent/metastatic head and neck squamous

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma

March 7, 2022

By clique_admin

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in

A Study of Pembrolizumab With or Without Lenvatinib as First Line Intervention in a Programmed Cell Death-ligand 1 Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

March 7, 2022

By clique_admin

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck

Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma

March 7, 2022

By clique_admin

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility